SCA
IMGN

Secor Capital Advisors’s Immunogen Inc IMGN Stock Holding History

Secor Capital Advisors’s Portfolio IMGN Stock Details IMGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-104,547
Closed -$800K – 608
2017
Q3 		$800K Buy
+104,547
New +$695K 0.08% 295

Other funds holding IMGN

ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Secor Capital Advisors's IMGN Position: Q4 2017 in Review

Secor Capital Advisors sold out of Immunogen Inc (IMGN) in Q4 2017, closing a stake of 104,547 shares — an estimated $800K sold.

Secor Capital Advisors first reported a position in IMGN in Q3 2017 and held it in 1 quarter. The position peaked at $800K in Q3 2017. 200 funds tracked by Wall St. Rank hold IMGN as of Q4 2017.

  • Secor Capital Advisors reported no remaining Immunogen Inc position as of Q4 2017 after selling out during the quarter.
  • Secor Capital Advisors sold 104,547 Immunogen Inc shares in Q4 2017, an estimated $800K.
  • Secor Capital Advisors first reported a position in Immunogen Inc in Q3 2017 and held it in 1 quarter.
  • Secor Capital Advisors's Immunogen Inc position peaked at $800K in Q3 2017.
  • 200 funds tracked by Wall St. Rank held Immunogen Inc as of Q4 2017.

Based on Secor Capital Advisors's 13F filing for Q4 2017, filed 14 Feb 2018.